Participant flow

Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer · Source last updated 2018-09-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Eribulin mesylate (1.4 mg/m2) administered intravenously (IV) over 2-5 minutes on days 1 and 8 of a 21 day cycle. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

   id

   FG000

   title

   Treatment (Eribulin Mesylate)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         29

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         29

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Twenty-nine patients were consented and treated.

recruitment Details

Seattle Cancer Care Alliance/University of Washington Phase II open label study enrolled patients at a single site between May 2012 and August 2015.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice